Botanix Pharmaceuticals (BOT) Q2 2026 TU earnings summary

Executive summary

• Achieved strong revenue growth and transitioned from a development-stage to a revenue-generating company, with cumulative gross sales reaching $93.5 million and net revenue at $21.2 million in the 11 months since Sofdra's launch.

• Sofdra, the first and only FDA-approved new chemical entity for primary axillary hyperhidrosis, has seen rapid adoption, with 62,500 prescriptions filled and refill rates 2.5 times the industry standard.

• Sales force expanded from 27 to 50 professionals, driving increased market penetration, prescription growth, and leveraging an innovative fulfillment platform.

• Market research indicates 90% of surveyed healthcare professionals expect to increase Sofdra prescribing in the next six months.

• Patent protection for Sofdra is extended to 2040, supporting long-term growth.

Financial highlights

• Net revenue rose 28% quarter-over-quarter to $9.1 million in Q2 FY26, up from $7.1 million in Q1 FY26.

• Gross-to-net yield improved to 24% in Q2 from 23% in Q1, with a target of 30%-40% over time.

• Operating cash outflow increased to $17.2 million in Q2 FY26, mainly due to sales force expansion and one-time costs.

• Inventory at $27.5 million supports anticipated higher prescription volumes and Q3 FY26 sales growth.

• Available funding totals $46.4 million, including $31.5 million in cash and $14.9 million in undrawn debt.

Outlook and guidance

• Expect continued strong revenue and prescription growth, supported by expanded sales force, fulfillment platform, and high refill rates.

• Focused on achieving break-even and optimizing production efficiency, with cost of goods expected to decrease 25%-40% through alternate API suppliers.

• Confident in future growth, with patent protection for Sofdra until 2040.

• Inventory and funding are sufficient to meet rising demand, with further API purchases planned.

• Clear path to profitability as sales and marketing investments drive revenue growth.